Treating multiple sclerosis with monoclonal antibodies: a 2010 update

References

• Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev. Neurother.8(3), 433–455 (2008).
   PubMedGoogle Scholar
• Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology73(17), 1418–1419 (2009).
   PubMed Web of Science ®Google Scholar
• Stuve O, Wiendl H. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected? Neurology73(17), 1346–1347 (2009).
   PubMed Web of Science ®Google Scholar
• Gutwinski S, Erbe S, Munch C, Janke O, Muller U, Haas J. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology74(6), 521–523 (2010).
   PubMed Web of Science ®Google Scholar
• Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis.199(6), 837–846 (2009).
   PubMed Web of Science ®Google Scholar
• Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol.71(1), 115–123 (2003).
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med.61, 35–47 (2010).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Polman CH, O’Connor PW et al. Evaluation of natalizumab treatment on the presence of JC virus in blood and urine from multiple sclerosis patients. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009 (P883).
   Google Scholar
• Dominguez-Mozo MI, Alvarez-Lafuente R, Garcia-Montojo M et al. JC virus in multiple sclerosis patients treated with natalizumab. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009 (P315).
   Google Scholar
• Gorelik L, Goelz S, Sandrock AW. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med.361(25), 2487–2488; author reply 2489–2490 (2009).
   PubMed Web of Science ®Google Scholar
• Chen Y, Bord E, Tompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med.361(11), 1067–1074 (2009).
   PubMed Web of Science ®Google Scholar
• Sadiq SA, Puccio LM, Brydon EW. JCV detection in multiple sclerosis patients treated with natalizumab. J. Neurol. (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol.6(5), 431–441 (2007).
   PubMed Web of Science ®Google Scholar
• Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H. JC virus detection in bodily fluids: clues to transmission. Clin. Infect. Dis.43(1), e9–e12 (2006).
   PubMed Web of Science ®Google Scholar
• Marzocchetti A, Tompkins T, Clifford DB et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology73(19), 1551–1558 (2009).
   PubMed Web of Science ®Google Scholar
• Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain127(Pt 9), 1970–1978 (2004).
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Du Pasquier RA, Kuroda MJ et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J. Immunol.168(1), 499–504 (2002).
   PubMed Web of Science ®Google Scholar
• Jilek S, Jaquiery E, Hirsch HH et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol.9(3), 264–272 (2010).
   PubMed Web of Science ®Google Scholar
• Haghikia A, Pappas D, Pula B et al. Assessment of a possible bioenergetic marker of cellular immunocompetence in MS patients undergoing immunotherapy: longitudinal analyses. Presented at: 61st Annual Meeting of the American Academy of Neurology. Seattle, USA, 25 April–2 May 2009.
   Google Scholar
• Varnier OE, McDermott JL, Giacomazzi CG et al. Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifies two PML cases in HIV and congenital immunodeficiency patients. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009 (P889).
   Google Scholar
• Schulick RD, Weir MB, Miller MW, Cohen DJ, Bermas BL, Shearer GM. Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation56(3), 590–596 (1993).
   PubMed Web of Science ®Google Scholar
• Kowalski R, Post D, Schneider MC et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin. Transplant.17(2), 77–88 (2003).
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum.60(12), 3761–3765 (2009).
   PubMed Web of Science ®Google Scholar
• d’Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann. Neurol.55(3), 320–328 (2004).
   PubMed Web of Science ®Google Scholar
• Engsig FN, Hansen AB, Omland LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis.199(1), 77–83 (2009).
   PubMed Web of Science ®Google Scholar
• Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol.17(3), 365–370 (2004).
   PubMed Web of Science ®Google Scholar
• Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann. Intern. Med.107(1), 78–87 (1987).
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, Ammassari A et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J. Infect. Dis.182(4), 1077–1083 (2000).
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Lorenzini P et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J. Neurovirol.9(Suppl. 1), 47–53 (2003).
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat. Clin. Pract. Neurol.2(10), 557–565 (2006).
   PubMedGoogle Scholar
• McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology72(9), 835–841 (2009).
   PubMed Web of Science ®Google Scholar
• Sidhu N, McCutchan JA. Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J. Neuroimmunol.219(1–2), 100–104 (2010).
   PubMed Web of Science ®Google Scholar
• Perumal J, Hreha S, Bao F et al. Post-natalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI findings. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009 (P418).
   Google Scholar
• Linda H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med.361(11), 1081–1087 (2009).
   PubMed Web of Science ®Google Scholar
• Wenning W, Haghikia A, Laubenberger J et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med.361(11), 1075–1080 (2009).
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol.10(8), 816–824 (2009).
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood113(20), 4834–4840 (2009).
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun. Rev.8(2), 144–146 (2008).
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med.353(4), 375–381 (2005).
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med.353(4), 369–374 (2005).
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A et al. GLANCE: results of a Phase 2, randomized, double-blind, placebo-controlled study. Neurology72(9), 806–812 (2009).
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Polman CH, Goodman AD et al. Efficacy and safety of natalizumab in the STRATA study. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009.
   Google Scholar
• Stuve O, Cravens PD, Frohman EM et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology72(5), 396–401 (2009).
   PubMed Web of Science ®Google Scholar
• Schiess N, Calabresi PA. Natalizumab: bound to rebound? Neurology72(5), 392–393 (2009).
   PubMed Web of Science ®Google Scholar
• Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology70(13 Pt 2), 1150–1151 (2008).
   PubMed Web of Science ®Google Scholar
• Tubridy N, Behan PO, Capildeo R et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology53(3), 466–472 (1999).
   PubMed Web of Science ®Google Scholar
• Gold R, Hartung HP, Hohlfeld R et al. [Therapy of multiple sclerosis with monoclonal antibodies – results and recommendations of a workshop of the medical advisory board of the German Multiple Sclerosis Society]. Aktuelle Neurologie36(7), 334–344 (2009).
   Web of Science ®Google Scholar
• De Luca A, Ammassari A, Pezzotti P et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. Aids22(14), 1759–1767 (2008).
   PubMed Web of Science ®Google Scholar
• Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J. Neurovirol.4(4), 451–456 (1998).
   PubMed Web of Science ®Google Scholar
• Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N. Engl. J. Med.338(19), 1345–1351 (1998).
   PubMed Web of Science ®Google Scholar
• Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother.53(5), 1840–1849 (2009).
   PubMed Web of Science ®Google Scholar
• Elphick GF, Querbes W, Jordan JA et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science306(5700), 1380–1383 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hara BA, Atwood WJ. Interferon β1-a and selective anti-5HT2a receptor antagonists inhibit infection of human glial cells by JC virus. Virus Res.132(1–2), 97–103 (2008).
   PubMed Web of Science ®Google Scholar
• Lima MA, Auriel E, Wuthrich C, Borenstein NM, Koralnik IJ. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin. Infect. Dis.41(3), 417–419 (2005).
   PubMed Web of Science ®Google Scholar
• Verma S, Cikurel K, Koralnik IJ et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J. Infect. Dis.196(5), 709–711 (2007).
   PubMed Web of Science ®Google Scholar
• Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI). Aliment. Pharmacol. Ther. (2010) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica89(12), 1476–1483 (2004).
   PubMed Web of Science ®Google Scholar
• Mone AP, Cheney C, Banks AL et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia20(2), 272–279 (2006).
   PubMed Web of Science ®Google Scholar
• Smolewski P, Szmigielska-Kaplon A, Cebula B et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma46(1), 87–100 (2005).
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, LaPlant BR et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res.32(12), 1849–1856 (2008).
   PubMed Web of Science ®Google Scholar
• Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol.35(11), 3332–3342 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol.30(1), 99–105 (2010).
   PubMed Web of Science ®Google Scholar
• Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med.192(10), 1453–1466 (2000).
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology128(2), 260–270 (2009).
   PubMed Web of Science ®Google Scholar
• Wray S. A descriptive analysis of infectious adverse events in alemtuzumab-treated multiple sclerosis patients. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9–12 September 2009 (P812).
   Google Scholar
• Jones JL, Coles AJ. Spotlight on alemtuzumab. Int. MS J.16(3), 77–81 (2009).
   PubMedGoogle Scholar
• Chen F, Day SL, Metcalfe RA et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore)84(2), 98–106 (2005).
   PubMed Web of Science ®Google Scholar
• Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol.20(2), 349–360 (2007).
   PubMed Web of Science ®Google Scholar
• Jubault V, Penfornis A, Schillo F et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J. Clin. Endocrinol. Metab.85(11), 4254–4257 (2000).
   PubMed Web of Science ®Google Scholar
• Krupica T Jr, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clin. Immunol.120(2), 121–128 (2006).
   PubMed Web of Science ®Google Scholar
• Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann. Rheum. Dis.67(Suppl. 3), iii83–iii86 (2008).
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest.119(7), 2052–2061 (2009).
   PubMed Web of Science ®Google Scholar
• Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract. Res. Clin. Endocrinol. Metab.23(6), 693–702 (2009).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359(17), 1786–1801 (2008).
   PubMed Web of Science ®Google Scholar
• Coles AJ. Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9–12 September 2009.
   Google Scholar
• Hirst CL, Pace A, Pickersgill TP et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J. Neurol.255(2), 231–238 (2008).
   PubMed Web of Science ®Google Scholar
• Selmaj K. Immunogenicity of alemtuzumab treatment for relapsing–remitting multiple sclerosis: no effect on efficacy or safety. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9–12 September 2009 (P811).
   Google Scholar
• Ooi JD, Holdsworth SR, Kitching AR. Advances in the pathogenesis of Goodpasture’s disease: from epitopes to autoantibodies to effector T cells. J. Autoimmun.31(3), 295–300 (2008).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol.253(1), 98–108 (2006).
   PubMed Web of Science ®Google Scholar
• Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur. J. Neurol.16(4), e70–e71 (2009).
   Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med.358(7), 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol.66(4), 460–471 (2009).
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol.61(1), 14–24 (2007).
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Shochat T, Weiss S, Ladkani D. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J. Neurol. Sci.286(1–2), 92–98 (2009).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol.63(3), 395–400 (2008).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology66(10), 1485–1489 (2006).
   PubMed Web of Science ®Google Scholar
• Bradl M, Misu T, Takahashi T et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol.66(5), 630–643 (2009).
   PubMed Web of Science ®Google Scholar
• Cayrol R, Saikali P, Vincent T. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann. NY Acad. Sci.1173, 478–486 (2009).
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Nakatsuji Y, Kimura T et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun.386(4), 623–627 (2009).
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology64(7), 1270–1272 (2005).
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol.65(11), 1443–1448 (2008).
   PubMed Web of Science ®Google Scholar
• Kausar F, Mustafa K, Sweis G et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin. Biol. Ther.9(7), 889–895 (2009).
   PubMed Web of Science ®Google Scholar
• van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin’s lymphoma. Neth. J. Med.67(7), 251–259 (2009).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum.58(9), 2652–2661 (2008).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Marlton P, Vitolo U et al. Interim results of a Phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-hodgkin’s lymphoma. Blood110, 199A (2007).
   Google Scholar
• van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol.115(4), 807–811 (2001).
   PubMed Web of Science ®Google Scholar
• Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs18(4), 491–500 (2009).
   PubMed Web of Science ®Google Scholar
• Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr. Opin. Mol. Ther.10(3), 294–309 (2008).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1–2 study. Blood111(3), 1094–1100 (2008).
   PubMed Web of Science ®Google Scholar
• Traynor K. Ofatumumab approved for advanced CLL. Am. J. Health Syst. Pharm.66(23), 2062 (2009).
   Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a Phase 1/2 trial. Blood111(12), 5486–5495 (2008).
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Baslund B, Rigby W et al. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: early results from an ongoing, double-blind, randomized, placebo-controlled clinical trial. Presented at: ACR/ARHP 2007 Annual Scientific Meeting. Boston, USA, 6–11 November 2007.
   Google Scholar
• Ostergaard M, Baslund B, Rigby W et al. Efficacy of ofatumumab in rheumatoid arthritis (RA) patients with inadequate response to one or more DMARDS: 48 weeks follow-up. Presented at: ACR/ARHP 2008 Annual Scientific Meeting. San Francisco, CA, USA, 24–29 October 2008.
   Google Scholar
• Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood104(6), 1793–1800 (2004).
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol.177(1), 362–371 (2006).
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol.183(1), 749–758 (2009).
   PubMed Web of Science ®Google Scholar
• Uchiyama S, Suzuki Y, Otake K et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci.101(1), 201–209 (2009).
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood101(3), 1045–1052 (2003).
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol.140(3), 303–312 (2008).
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol.66(4), 460–471 (2009).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA103(15), 5941–5946 (2006).
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon b. Lancet Neurol.9(4), 381–390 (2010).
   PubMed Web of Science ®Google Scholar
• Sheridan J, Elkins J, Zhang Y et al. Expansion of CD56bright NK cells correlates with therapeutic response to daclizumab in multiple sclerosis. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9–12 September 2009 (P430).
   Google Scholar
• Oh U, Blevins G, Griffith C et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol.66(4), 471–479 (2009).
   PubMed Web of Science ®Google Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med.199(7), 971–979 (2004).
   PubMed Web of Science ®Google Scholar
• Haas J, Hug A, Viehover A et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol.35(11), 3343–3352 (2005).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Howard T, Packer AN et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol.66(4), 483–489 (2009).
   PubMed Web of Science ®Google Scholar
• Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Daclizumab in treatment of multiple sclerosis patients. Mult. Scler.15(2), 272–274 (2009).
   PubMed Web of Science ®Google Scholar
• Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs69(9), 1141–1152 (2009).
   PubMed Web of Science ®Google Scholar
• Weber J, Keam SJ. Ustekinumab. BioDrugs23(1), 53–61 (2009).
   PubMed Web of Science ®Google Scholar
• Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin. Immunol.19(6), 362–371 (2007).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet371(9625), 1665–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet371(9625), 1675–1684 (2008).
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature421(6924), 744–748 (2003).
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med.201(2), 233–240 (2005).
   PubMed Web of Science ®Google Scholar
• Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med.187(4), 537–546 (1998).
   PubMed Web of Science ®Google Scholar
• Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med.184(2), 771–775 (1996).
   PubMed Web of Science ®Google Scholar
• Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl Acad. Sci. USA94(2), 599–603 (1997).
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol.176(12), 7768–7774 (2006).
   PubMed Web of Science ®Google Scholar
• Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med.8(5), 500–508 (2002).
   PubMed Web of Science ®Google Scholar
• Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine5(6), 583–588 (1993).
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol.7(9), 796–804 (2008).
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev. Neurother.9(3), 319–321 (2009).
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P. Cracking the BAFF code. Nat. Rev. Immunol.9(7), 491–502 (2009).
   PubMed Web of Science ®Google Scholar
• Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J. Immunol.183(6), 3561–3567 (2009).
   PubMed Web of Science ®Google Scholar
• Kikly K, Manetta J, Smith H, Wierda D, Witcher D. Characterization of LY2127399, a neutralizing antibody for BAFF. Presented at: ACR/ARHP 2009 Annual Scientific Meeting. PA, USA, 17–21 October 2009.
   Google Scholar
• Genovese MC, Mociran E, Biagini M, Bojin S, Sloan-Lancaster J. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). Presented at: ACR/ARHP 2009 Annual Scientific Meeting. PA, USA, 17–21 October 2009.
   Google Scholar
• Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol.148(1–2), 11–23 (2004).
   PubMed Web of Science ®Google Scholar
• Huntington ND, Tomioka R, Clavarino C et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int. Immunol.18(10), 1473–1485 (2006).
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med.201(2), 195–200 (2005).
   PubMed Web of Science ®Google Scholar
• Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun.8, 243–265 (2005).
   PubMedGoogle Scholar
• Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J. Neuroimmunol.152(1–2), 183–190 (2004).
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Faber H, Steinmeyer F et al. Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain131(Pt 6), 1455–1463 (2008).
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon β-1b. Arch. Neurol.54(9), 1169–1190 (1997).
   PubMed Web of Science ®Google Scholar
• Rotondi M, Mazziotti G, Biondi B et al. Long-term treatment with Interferon-β therapy for multiple sclerosis and occurrence of Graves' disease. J. Endocrinol. Invest.23(5), 321–324 (2000).
   PubMed Web of Science ®Google Scholar
• Caraccio N, Dardano A, Manfredonia F et al. Long-term follow-up of 106 multiple sclerosis patients undergoing Interferon-β 1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab.90(7), 4133–4137 (2005).
   PubMed Web of Science ®Google Scholar
• Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult. Scler.15(12), 1532–1533 (2009).
   PubMed Web of Science ®Google Scholar
• Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J. Neurol.256(10), 1771–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N. Engl. J. Med.358(6), 647–648 (2008).
   PubMed Web of Science ®Google Scholar
• Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol.66(3), 403–406 (2009).
   PubMed Web of Science ®Google Scholar
• Martinelli V, Radaelli M, Straffi L, Rodegher M, Comi G. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol. Sci.30(Suppl. 2), S167–S170 (2009).
   PubMed Web of Science ®Google Scholar
• Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab Phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology69(8), 785–789 (2007).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 416–426 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother.5(6), 721–727 (2005).
   PubMedGoogle Scholar
• Cook S, Vermersch P, Comi G et al. Safety and tolerability of cladribine tablets in relapsing–remitting multiple sclerosis during the 96-week, Phase III, double-blind, placebo-controlled CLARITY study. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009.
   Google Scholar
• Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med.355(11), 1124–1140 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66(6), 894–900 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman M, Wolinsky JS, Byrnes WJ et al. Oral Teriflunomide or placebo added to interferon β for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9–12 September 2009.
   Google Scholar
• Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet371(9630), 2085–2092 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet372(9648), 1463–1472 (2008).
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology73(12), 984–990 (2009).
   PubMed Web of Science ®Google Scholar